CXCR2 and neoplasm: As shown in Figure 5C, both MDA-PCa-2b-CXCR1 (5.075 ± 1.284) and MDA-PCa-2b-CXCR2 (5.175 ± 1.162) showed a significant reduction in tumor infiltrating CD45+ cells relative to MDA-PCa-2b-Vec (8.150 ± 1.471).